Literature DB >> 26573280

Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study.

Paolo Baili1, Francesca Di Salvo2, Francesco de Lorenzo3, Francesco Maietta4, Carmine Pinto5,6, Vera Rizzotto4, Massimo Vicentini7,8, Paolo Giorgi Rossi7,8, Rosario Tumino9, Patrizia Concetta Rollo9, Giovanna Tagliabue10, Paolo Contiero10, Pina Candela11, Tiziana Scuderi11, Elisabetta Iannelli3, Stefano Cascinu6, Fulvio Aurora12, Roberto Agresti13, Alberto Turco1, Milena Sant1, Elisabetta Meneghini1, Andrea Micheli1,14.   

Abstract

PURPOSE: To illustrate the out-of-pocket (OOP) costs incurred by a population-based group of patients from 5 to 10 years since their cancer diagnosis in a country with a nationwide public health system.
METHODS: Interviews on OOP costs to a sample of 5-10 year prevalent cases randomly extracted from four population-based cancer registries (CRs), two in the north and two in the south of Italy. The patients' general practitioners (GPs) gave assurance about the patient's physical and psychological condition for the interview. A zero-inflated negative binomial model was used to analyze OOP cost determinants.
RESULTS: Two hundred six cancer patients were interviewed (48 % of the original sample). On average, a patient in the north spent €69 monthly, against €244 in the south. The main differences are for transport, room, and board (TRB) to reach the hospital and/or the cancer specialist (north €0; south €119). Everywhere, OOP costs without TRB costs were higher for patients with a low quality of life.
CONCLUSIONS: Despite the limited participation, our study sample's characteristics are similar to those of the Italian cancer prevalence population, allowing us to generalize the results. The higher OOP costs in the south may be due to the scarcity of oncologic structures, obliging patients to seek assistance far from their residence. Implications for cancer survivors Cancer survivors need descriptive studies to show realistic data about their status. Future Italian and European descriptive studies on cancer survivorship should be based on population CRs and involve GPs in order to approach the patient at best.

Entities:  

Keywords:  Cancer prevalence; Cancer registry; Cancer survivorship; Out-of-pocket costs

Mesh:

Year:  2015        PMID: 26573280     DOI: 10.1007/s00520-015-3019-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.359


  16 in total

1.  Cancer survivors: a booming population.

Authors:  Carla Parry; Erin E Kent; Angela B Mariotto; Catherine M Alfano; Julia H Rowland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

2.  Cancer rehabilitation indicators for Europe.

Authors:  Paolo Baili; Josette Hoekstra-Weebers; Elke Van Hoof; Hans Helge Bartsch; Luzia Travado; Miklos Garami; Francesca Di Salvo; Andrea Micheli; Piret Veerus
Journal:  Eur J Cancer       Date:  2012-12-10       Impact factor: 9.162

3.  Levels of acute health service use among cancer survivors in the United Kingdom.

Authors:  Jacob Maddams; Martin Utley; Henrik Møller
Journal:  Eur J Cancer       Date:  2011-05-16       Impact factor: 9.162

4.  EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

Authors:  Milena Sant; Claudia Allemani; Mariano Santaquilani; Arnold Knijn; Francesca Marchesi; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2009-01-24       Impact factor: 9.162

5.  Contrasts in cancer prevalence in Connecticut, Iowa, and Utah.

Authors:  Andrea Micheli; Rosemary Yancik; Vittorio Krogh; Arduino Verdecchia; Milena Sant; Riccardo Capocaccia; Franco Berrino; Lynn Ries
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

6.  Cancer prevalence in European registry areas.

Authors:  A Micheli; E Mugno; V Krogh; M J Quinn; M Coleman; T Hakulinen; G Gatta; F Berrino; R Capocaccia
Journal:  Ann Oncol       Date:  2002-06       Impact factor: 32.976

7.  Cancer prevalence estimates in Europe at the beginning of 2000.

Authors:  G Gatta; S Mallone; J M van der Zwan; A Trama; S Siesling; R Capocaccia
Journal:  Ann Oncol       Date:  2013-04-03       Impact factor: 32.976

8.  Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group.

Authors:  A Micheli; S Francisci; V Krogh; A G Rossi; P Crosignani
Journal:  Tumori       Date:  1999 Sep-Oct

9.  Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types.

Authors:  L Dal Maso; S Guzzinati; C Buzzoni; R Capocaccia; D Serraino; A Caldarella; A P Dei Tos; F Falcini; M Autelitano; G Masanotti; S Ferretti; F Tisano; U Tirelli; E Crocetti; R De Angelis; S Virdone; A Zucchetto; A Gigli; S Francisci; P Baili; G Gatta; M Castaing; R Zanetti; P Contiero; E Bidoli; M Vercelli; M Michiara; M Federico; G Senatore; F Pannozzo; M Vicentini; A Bulatko; D R Pirino; M Gentilini; M Fusco; A Giacomin; A C Fanetti; R Cusimano
Journal:  Ann Oncol       Date:  2014-08-22       Impact factor: 32.976

10.  Cancer prevalence estimates in Italy from 1970 to 2010.

Authors:  Roberta De Angelis; Enrico Grande; Riccardo Inghelmann; Silvia Francisci; Andrea Micheli; Paolo Baili; Elisabetta Meneghini; Riccardo Capocaccia; Arduino Verdecchia
Journal:  Tumori       Date:  2007 Jul-Aug
View more
  6 in total

Review 1.  A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can't Pay the Co-Pay.

Authors:  Louisa G Gordon; Katharina M D Merollini; Anthony Lowe; Raymond J Chan
Journal:  Patient       Date:  2017-06       Impact factor: 3.883

2.  Out-of-pocket-payments and the financial burden of 502 cancer patients of working age in Germany: results from a longitudinal study.

Authors:  Matthias Büttner; Hans-Helmut König; Margrit Löbner; Susanne Briest; Alexander Konnopka; Andreas Dietz; Steffi Riedel-Heller; Susanne Singer
Journal:  Support Care Cancer       Date:  2018-10-12       Impact factor: 3.603

Review 3.  The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.

Authors:  Nicolas Iragorri; Claire de Oliveira; Natalie Fitzgerald; Beverley Essue
Journal:  Curr Oncol       Date:  2021-03-15       Impact factor: 3.677

4.  The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients.

Authors:  Katja Mehlis; Julian Witte; Bastian Surmann; Matthias Kudlich; Leonidas Apostolidis; Jürgen Walther; Dirk Jäger; Wolfgang Greiner; Eva C Winkler
Journal:  BMC Cancer       Date:  2020-06-05       Impact factor: 4.430

5.  Socioeconomic deprivation worsens the outcomes of Italian women with hormone receptor-positive breast cancer and decreases the possibility of receiving standard care.

Authors:  Francesca Di Salvo; Nicola Caranci; Teresa Spadea; Nicolas Zengarini; Pamela Minicozzi; Hade Amash; Mario Fusco; Fabrizio Stracci; Fabio Falcini; Claudia Cirilli; Giuseppina Candela; Rosanna Cusimano; Rosario Tumino; Milena Sant
Journal:  Oncotarget       Date:  2017-07-22

6.  Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study.

Authors:  Matthias Büttner; Susanne Singer; Leopold Hentschel; Stephan Richter; Peter Hohenberger; Bernd Kasper; Dimosthenis Andreou; Daniel Pink; Kathy Taylor; Karin Arndt; Martin Bornhäuser; Jochen Schmitt; Markus K Schuler; Martin Eichler
Journal:  Support Care Cancer       Date:  2021-07-11       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.